Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC. Tew WP, et al. Among authors: lheureux s. J Clin Oncol. 2020 Oct 20;38(30):3468-3493. doi: 10.1200/JCO.20.01924. Epub 2020 Aug 13. J Clin Oncol. 2020. PMID: 32790492 Free PMC article.
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, Wang L, McGill S, Ivy SP, Oza AM. Hirte H, et al. Among authors: lheureux s. Gynecol Oncol. 2015 Jul;138(1):55-61. doi: 10.1016/j.ygyno.2015.04.009. Epub 2015 Apr 17. Gynecol Oncol. 2015. PMID: 25895616 Clinical Trial.
Safety evaluation of olaparib for treating ovarian cancer.
Lheureux S, Bowering V, Karakasis K, Oza AM. Lheureux S, et al. Expert Opin Drug Saf. 2015 Aug;14(8):1305-16. doi: 10.1517/14740338.2015.1045875. Epub 2015 Jun 8. Expert Opin Drug Saf. 2015. PMID: 26051946 Review.
Ovarian cancer treatment: The end of empiricism?
Lheureux S, Karakasis K, Kohn EC, Oza AM. Lheureux S, et al. Cancer. 2015 Sep 15;121(18):3203-11. doi: 10.1002/cncr.29481. Epub 2015 Jun 10. Cancer. 2015. PMID: 26096019 Free PMC article. Review.
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM. Lheureux S, et al. Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21. Clin Cancer Res. 2017. PMID: 28223274 Clinical Trial.
Niraparib for the treatment of ovarian cancer.
Kanjanapan Y, Lheureux S, Oza AM. Kanjanapan Y, et al. Among authors: lheureux s. Expert Opin Pharmacother. 2017 Apr;18(6):631-640. doi: 10.1080/14656566.2017.1297423. Epub 2017 Apr 7. Expert Opin Pharmacother. 2017. PMID: 28299955 Review.
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME. Samimi G, et al. Among authors: lheureux s. J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11. J Clin Oncol. 2017. PMID: 28398847 Free PMC article.
174 results